Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on Exact Sciences (NASDAQ:EXAS) but lowers the price target from $88 to $75.

July 17, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on Exact Sciences but lowers the price target from $88 to $75.
The maintained Buy rating suggests continued confidence in the company's long-term prospects, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100